Behavioral Activation for Depression and Habitual Rumination
- Disease/Condition
- Major Depressive Disorder
- Drug/Device/Intervention
- Behavioural Activation (BA)
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- Ragnar Pétur Ólafsson
- Funder
- University of Iceland
- Location
- Reykjavík, Iceland
- Phase
- N/A
- Start date
- Feb 09, 2024
- End date
- Feb 01, 2026
- Enrollment
- 130 participants
Symptom severity measured by the BDI-2,Disorder severity assessed with the DIAMOND diagnostic interview - Major Depressive Disorder,Diagnostic status assessed with the DIAMOND diagnostic interview - Major Depressive Episode
Depressive rumination, a negative thinking style characterized by repetitive and passive
 thoughts about the causes, meanings, and consequences of one's feelings and distress, is
 often described as being a habitual response tendency that forms a vulnerability to
 depression. Behavioural Activation (BA) is an effective treatment for depression but little
 is known of mechanisms of changes during a successful treatment completion and for whom the
 treatment benefits the most. The main purpose of the study is to investigate whether
 habit-like mood-reactive rumination will change during Behavioral Activation treatment for
 current depression and mediates symptom changes in the treatment. Important moderators of
 change will also be investigated (i.e. history of early life stress and cognitive
 flexibility). We aim to provide individual BA treatment for up to 130 currently depressed
 participants in 12 treatment sessions over 11 weeks. Measures are obtained at pre-treatment,
 during treatment, at post-treatment and at 6 month follow up.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06322420
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06322420 through Pure Global AI's free database. This phase not specified trial is sponsored by Ragnar Pétur Ólafsson and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 130 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.